Product Description
Mechanisms of Action: SHP-2 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Teikoku
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TK-042](https://pryzm-maps.s3.us-west-2.amazonaws.com/7current_maps.png)
Countries in Clinic: Japan
Active Clinical Trial Count: 1
Highest Development Phases
Phase 3: Rhinitis, Allergic, Perennial
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
jRCT2031240126 | P3 |
Not yet recruiting |
Rhinitis, Allergic, Perennial |
2025-03-31 |